在中和单克隆抗体治疗后,长期抗SARS-CoV-2抗体轨迹

Elizabeth S Munroe1, Greg A Grandits2, Robert C Hyzy1

  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.

PloS one
|June 18, 2025
PubMed
概括

针对COVID-19的中和单克隆抗体 (nMAbs) 并没有抑制长期免疫反应. 与安慰剂相比,接受nMAbs治疗的患者表现出类似的抗核囊抗体水平,这表明内源性幽默免疫力没有受损.